Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
bL4qr4U23SJCvAEQ
